Last Updated: November 16, 2026

Details for Patent: 7,498,343

« Back to Dashboard


Which drugs does patent 7,498,343 protect, and when does it expire?

Patent 7,498,343 protects SIRTURO and is included in one NDA.

This patent has fifty-seven patent family members in thirty-five countries.

Summary for Patent: 7,498,343
Title:Mycobacterial inhibitors
Abstract:The present invention relates to novel substituted quinoline derivatives according to the general Formula (Ia) or the general Formula (Ib) the pharmaceutically acceptable acid or base addition salts thereof, the stereochemically isomeric forms thereof, the tautomeric forms thereof and the N-oxide forms thereof. The claimed compounds are useful for the treatment of mycobacterial diseases, particularly those diseases caused by pathogenic mycobacteria such as Mycobacterium tuberculosis, M. bovis, M. avium and M. marinum. In particular, compounds are claimed in which, independently from each other, R1 is bromo, p=1, R2 is alkyloxy, R3 is optionally substituted naphthyl or phenyl, q=1, R4 and R5 each independently are hydrogen, methyl or ethyl, R6 is hydrogen, r is equal to 0 or 1 and R7 is hydrogen. Also claimed is a composition comprising a pharmaceutically acceptable carrier and, as active ingredient, a therapeutically effective amount of the claimed compounds, the use of the claimed compounds or compositions for the manufacture of a medicament for the treatment of mycobacterial diseases and a process for preparing the claimed compounds.
Inventor(s):Jozef Frans Elisabetha Van Gestel, Jérôme Emile Georges Guillemont, Marc Gaston Venet, Hervé Jean Joseph Poignet, Laurence Françoise Bernadette Decrane, Daniel F. J. Vernier, Frank Christopher Odds
Assignee: Janssen Pharmaceutica NV
Application Number:US11/007,026
Patent Claim Types:
see list of patent claims
Use; Composition;
Patent landscape, scope, and claims:

US Patent 7,498,343: Bedaquiline Patent Scope, Claims, Expiration, and Generic Risk

US Patent 7,498,343 protects a broad class of quinoline-derived anti-mycobacterial compounds, including bedaquiline, the active ingredient in Sirturo. Its core protection covers compound structure, selected stereoisomers and salts, pharmaceutical compositions, anti-mycobacterial treatment methods, and a synthesis process. The patent issued on March 3, 2009, and its listed US patent term expired on December 18, 2023. FDA pediatric exclusivity associated with Sirturo extended certain regulatory protections by six months, but did not create a new patent term. The patent is therefore no longer the principal US barrier to generic bedaquiline approval, although formulation, labeling, regulatory exclusivity, manufacturing, and supply-chain issues can still affect market entry.

What drug does US Patent 7,498,343 protect?

US Patent 7,498,343 is associated with bedaquiline, also known as TMC207 or R207910. The patent is assigned to Janssen Pharmaceutica NV and covers quinoline derivatives with anti-mycobacterial activity.[1]

Bedaquiline is a diarylquinoline that inhibits mycobacterial ATP synthase. FDA approved Sirturo on December 28, 2012, through New Drug Application 204384 for use with combination therapy in adults with pulmonary multidrug-resistant tuberculosis.[2] FDA later expanded the indication to include patients at least five years old and weighing at least 15 kilograms with pulmonary MDR-TB.[3]

The representative bedaquiline structure falls within the patent's Formula (Ia). The named compound is generally described as:

1-(6-bromo-2-methoxy-quinolin-3-yl)-4-dimethylamino-2-naphthalen-1-yl-1-phenyl-butan-2-ol.

The patent claims both broad chemical genera and narrower stereochemical and structural embodiments.

What are the main claim categories in US Patent 7,498,343?

The 24 claims divide into five principal categories.

Claim category Claims Scope
Chemical compounds 1-16, 20-22 Quinoline-based compounds, salts, stereoisomers, tautomers and N-oxides
Specific compounds 7-16 Named examples, formula-specific compounds and selected stereoisomers
Pharmaceutical compositions 17, 23 Compositions containing a compound and pharmaceutically acceptable carrier
Treatment methods 18, 24 Treating mycobacterial disease, including tuberculosis
Manufacturing process 19 Reacting Formula II and Formula III intermediates to produce a claimed compound

Claim 1 is the broadest independent compound claim. Claim 17 is an independent composition claim, claim 18 is an independent treatment-method claim, and claim 19 is an independent process claim. Claim 24 narrows the treatment method to tuberculosis.

How broad is claim 1?

Claim 1 is a large Markush genus. It covers compounds having Formula (Ia) or Formula (Ib), together with:

  • Pharmaceutically acceptable acid- or base-addition salts
  • Stereochemically isomeric forms
  • Tautomeric forms
  • N-oxide forms

The substituent definitions are extensive. R1 and R6 can include hydrogen, halogen, haloalkyl, cyano, hydroxy, aryl, heteroaryl, alkyl, alkoxy, alkylthio and related substituted groups. R3 can be alkyl, aryl, arylalkyl, heteroaryl or heteroarylalkyl. The terminal amino substituent can contain dimethylamino-type structures or cyclic amines.

The claim also permits substantial variation in:

  • Number and position of ring substituents
  • Aromatic and heteroaromatic groups
  • Alkyl and cycloalkyl groups
  • Amino substituents
  • Ring nitrogen substitution
  • Stereochemical configuration
  • Salt form and oxidation state

This breadth gives claim 1 substantial genus-level reach. It does not, however, mean every theoretical member of the Markush definition would necessarily be enforceable. In litigation, a defendant could challenge written description, enablement, indefiniteness, anticipation or obviousness for particular members or subgenuses.

What structural elements define the claimed chemistry?

The claimed compounds generally contain:

  1. A substituted quinoline or related heteroaromatic region.
  2. A tertiary alcohol-bearing carbon framework.
  3. An aryl or heteroaryl substituent.
  4. A dimethylamino or related aminoalkyl side chain.
  5. Optional stereochemical configurations and salt forms.

Bedaquiline's commercial structure uses a 6-bromo-2-methoxyquinoline, a naphthyl group, a phenyl group and a dimethylaminobutyl side chain. Claim 5 narrows the genus toward this commercial architecture by specifying bromo substitution at R1, an alkoxy group at R2, an aryl group at R3 and a one-carbon substitution pattern at q.

What do claims 2 through 7 add?

Claim 2 narrows the substituent definitions and limits several variables. It restricts R2, R3, the cyclic amino groups and the permitted aryl and heteroaryl systems.

Claim 3 narrows R6 to hydrogen, halogen or alkyl.

Claim 4 identifies a narrower set of preferred structures, including:

  • R1 as hydrogen, halogen, aryl, alkyl or alkoxy
  • p equal to 1
  • R2 as hydrogen, alkoxy or alkylthio
  • R3 as naphthyl, phenyl or thienyl
  • q equal to 0, 1, 2 or 3
  • Selected imidazolyl, triazolyl, piperidinyl, piperazinyl and thiomorpholinyl groups

Claim 5 is materially narrower and includes the commercial bedaquiline-type substitution pattern:

  • R1 is bromo
  • R2 is alkoxy
  • R3 is naphthyl or phenyl
  • q equals 1
  • R4 and R5 are hydrogen, methyl or ethyl
  • R6 is hydrogen

Claim 6 limits the compound to Formula (Ia).

Claim 7 lists eight specifically identified compounds. The listed compounds include difluorophenyl, naphthyl, fluorophenyl and p-tolyl variants, as well as dimethylamino and methylamino derivatives. These claims provide fallback positions if broader genus claims are challenged.

What do claims 8 through 16 protect?

Claims 8 through 16 focus on specific formula embodiments and biological or stereochemical selections. The structural images for these claims are not reproduced in the supplied text, so the exact substituent layouts cannot be reconstructed from the text alone. Their legal function is nevertheless clear.

Claims 8 and 9 identify a particular Formula (Ia) compound and a diastereoisomer characterized by a melting point of 210°C. Claim 10 selects the diastereoisomer with the higher pIC50 value in the Mycobacterium smegmatis assay.

Claims 11 through 14 select enantiomers based on biological performance:

  • Lowest MIC against M. tuberculosis
  • Highest pIC50 against M. smegmatis
  • MIC of 1 microgram/mL or less
  • pIC50 greater than 7.5

Claims 15 and 16 cover specified enantiomeric forms, including one characterized by an optical rotation of [alpha]D20 = -166.98 degrees in DMF.

These claims are narrower than claim 1 because they depend on a defined structural formula, stereochemical identity or measured biological property. Property-defined claims can be commercially important but may create proof issues in enforcement. A patent owner would need to establish that the accused product has the claimed stereochemistry and satisfies the relevant assay limitation.

Does US Patent 7,498,343 cover bedaquiline's stereochemistry?

Yes. The patent expressly covers stereochemically isomeric forms and contains claims directed to selected diastereomers and enantiomers. This matters because bedaquiline has stereogenic centers and its commercial activity depends on the stereochemical composition of the active ingredient.

A generic product that has the same active stereoisomer, or a therapeutically equivalent stereochemical mixture, could implicate the compound claims even if its salt, excipient system or manufacturing route differs.

Claims 9 through 16 are not limited to a commercial tablet formulation. They are directed primarily to chemical identity and stereochemistry.

What formulations are protected by the patent?

The patent contains composition claims but does not appear, from the supplied claims, to claim a detailed Sirturo tablet formulation, particle-size distribution, coating system, dissolution profile or specific excipient combination.

Claim 17 covers a composition comprising:

  • A pharmaceutically acceptable carrier
  • A therapeutically effective amount of a claim 1 compound

Claim 23 applies the same composition concept to a compound of claim 15.

These are broad composition claims. They can reach tablets, capsules or other dosage forms containing a covered compound, but they provide less formulation-specific protection than a patent directed to a particular solid dispersion, polymorph, dosage strength or excipient architecture.

The supplied claims do not identify a separate bedaquiline polymorph patent or a detailed formulation patent. That distinction is material for generic risk analysis because a generic applicant may avoid a narrow formulation claim while still facing a compound claim, subject to patent term and litigation status.

What method-of-use protection does the patent provide?

Claims 18 and 24 cover treatment methods. Claim 18 recites administering a therapeutically effective amount of a claimed compound to a patient suffering from a mycobacterial disease. Claim 24 narrows the disease to tuberculosis.

The method claims potentially cover use of bedaquiline for tuberculosis, including use in combination regimens if the administration falls within the claim language. They do not, based on the supplied text, require:

  • A particular companion drug
  • A defined treatment duration
  • A specific dosing schedule
  • A particular resistance genotype
  • A defined patient age or weight
  • A specific line of therapy

The commercial Sirturo indication has been narrower than the literal breadth of claim 24. FDA approval was directed to pulmonary MDR-TB in combination with other drugs, while the patent claim recites tuberculosis more generally.

What is the manufacturing and process scope?

Claim 19 covers a process in which a Formula II compound is reacted with a Formula III compound. The claim incorporates the substituent definitions from claim 1.

This process claim is narrower than the compound genus in one respect because it requires a particular synthetic relationship between the starting materials. It can still create risk for an API manufacturer if the manufacturing route uses the claimed intermediates and reaction sequence.

A manufacturer using a different route could avoid literal infringement of claim 19 while still producing a product that falls within claims 1, 5, 7 or the stereochemical claims. Process freedom therefore does not necessarily provide product freedom.

When did US Patent 7,498,343 expire?

The key dates are:

Event Date
Earliest priority date reported for the family December 18, 2002
US patent application publication 2005
US Patent 7,498,343 issued March 3, 2009
Sirturo FDA approval December 28, 2012
Listed US patent expiration December 18, 2023
Six-month pediatric regulatory extension Through approximately June 18, 2024

The Orange Book-listed patent expiration date is December 18, 2023.[4] The six-month pediatric extension is a regulatory exclusivity extension under the Hatch-Waxman framework. It can delay approval or marketing of an otherwise approvable generic, but it does not convert an expired patent into a new 20-year patent term.[5]

Patent-term calculations should distinguish:

  • Patent expiration
  • Patent-term adjustment
  • Patent-term extension under 35 U.S.C. § 156
  • Pediatric exclusivity under 21 U.S.C. § 355a
  • New chemical entity exclusivity
  • Orphan-drug exclusivity

These protections do not all operate in the same way.

What was the FDA exclusivity status of Sirturo?

Sirturo received FDA approval as a new chemical entity. The standard five-year NCE exclusivity period ran from December 28, 2012, to December 28, 2017, subject to statutory exceptions for certain Paragraph IV filings.

Sirturo also received orphan-drug designation for MDR-TB. Orphan exclusivity generally provides seven years of protection from approval for the designated indication, producing an approximate period through December 28, 2019.[6]

The relevant exclusivity timeline was therefore:

Protection Approximate end date Commercial effect
Five-year NCE exclusivity December 28, 2017 Restricted ANDA submission based on the same active moiety, subject to Paragraph IV rules
Seven-year orphan exclusivity December 28, 2019 Blocked approval of the same drug for the protected orphan indication, subject to statutory exceptions
US 7,498,343 patent term December 18, 2023 Blocked or exposed infringing product, composition, method and process activity
Pediatric exclusivity Approximately June 18, 2024 Added six months to applicable FDA exclusivity or patent-related barriers

What is the Orange Book status of US Patent 7,498,343?

US Patent 7,498,343 was listed in the FDA Orange Book for Sirturo. Its listing identified a drug-substance or drug-product patent associated with bedaquiline fumarate and carried an expiration date of December 18, 2023.[4]

The supplied patent claims are principally compound, composition, treatment-method and process claims. The Orange Book listing does not mean every claim necessarily covers every Sirturo presentation. Orange Book listing is a regulatory notice mechanism and is not a judicial determination of claim validity or infringement.

After expiration, the principal Orange Book patent barrier associated with this patent ceased. Any remaining risk would depend on other listed patents, unlisted patents, regulatory exclusivity, litigation settlements, or non-patent commercial barriers.

Were there Paragraph IV challenges to Sirturo?

The supplied record does not establish a specific US Paragraph IV litigation outcome involving US Patent 7,498,343. A Paragraph IV certification may be filed against an Orange Book-listed patent before expiration, but the presence of a certification does not prove that the patent was invalid, unenforceable or non-infringed.

The likely generic pathways were:

  1. An ANDA with a Paragraph IV certification before patent expiry.
  2. A post-expiry ANDA relying on the absence of remaining patent or exclusivity barriers.
  3. A 505(b)(2) application if the sponsor sought a materially different formulation, indication or clinical bridge.
  4. A product launch outside the United States without direct relevance to US patent clearance.

No biosimilar pathway applies. Bedaquiline is a chemically synthesized small molecule, not a biologic. US entry would ordinarily proceed through the ANDA pathway or, depending on the product and proposed labeling, a 505(b)(2) pathway.

Which companies are challenging or competing with Sirturo?

The principal competitive pressure comes from generic manufacturers and public-health suppliers rather than biosimilar developers. The competitive landscape includes:

  • Generic bedaquiline manufacturers
  • Regional suppliers serving tuberculosis programs
  • Alternative MDR-TB drugs such as pretomanid, delamanid and linezolid
  • Combination-regimen developers
  • Public procurement organizations

Janssen and Johnson & Johnson also entered access and supply arrangements designed to expand availability in low- and middle-income countries, including arrangements involving the Stop TB Partnership's Global Drug Facility.[7]

Those agreements affect commercial access and revenue exposure but do not expand the expired US patent term.

How strong is the patent estate for bedaquiline?

US Patent 7,498,343 was strong during its enforceable term because it combined several layers:

  • A broad compound genus
  • Narrower chemical subgenera
  • Named compounds
  • Stereochemical claims
  • Composition claims
  • Tuberculosis treatment claims
  • A manufacturing-process claim

The estate was less complete as a modern lifecycle portfolio because the supplied claims do not show a detailed formulation, polymorph, dosing-regimen or fixed-combination patent. The commercial compound claims provided the most important protection. Once the patent expired, the value of the remaining claims fell sharply unless another unexpired patent covered the product or its use.

What generic launch risks remain after patent expiration?

After December 18, 2023, and the associated pediatric-extension period, a generic bedaquiline applicant would face lower patent risk from US 7,498,343. Remaining issues could include:

  • Other Orange Book-listed patents
  • Regulatory exclusivity not tied to this patent
  • Product-specific formulation patents
  • Manufacturing patents covering a selected API route
  • FDA bioequivalence requirements
  • Salt, polymorph and impurity specifications
  • Supply-chain qualification
  • Controlled procurement channels for tuberculosis medicines
  • Labeling restrictions and indication carve-outs

The largest legal risk would shift from the expired core compound patent to any separate, unexpired patent family. The largest commercial risk would likely be market size, procurement pricing and limited US demand rather than basic compound claim coverage.

What patent litigation and settlement issues matter?

The key litigation issue is whether an ANDA sponsor challenged the patent before expiration and whether the patent owner entered a settlement that delayed launch. The supplied information does not establish a US settlement agreement or a launch date under any such settlement.

For business planning, the relevant questions are:

  • Whether a Paragraph IV notice was served
  • Whether a 30-month stay was triggered
  • Whether the patent owner sued within 45 days
  • Whether the case was dismissed, settled or adjudicated
  • Whether the settlement included a licensed entry date
  • Whether any agreement was submitted to the FTC under the applicable antitrust review framework

Without a documented US case or settlement, the patent itself supports an expiration-based analysis rather than a negotiated-entry analysis.

How does bedaquiline compare with other tuberculosis drugs?

Drug Class FDA pathway Patent landscape profile
Bedaquiline Diarylquinoline NDA 204384 Core US compound patent expired in 2023
Pretomanid Nitroimidazole NDA approval for combination regimen Combination and regimen-specific protection can be more important
Delamanid Nitro-dihydro-imidazooxazole Foreign and regional approvals Separate compound and formulation portfolios
Linezolid Oxazolidinone Generic small molecule Mature generic market with formulation and indication issues
Sutezolid Oxazolidinone investigational Development-stage Patent value remains tied to clinical development and claims

Bedaquiline's patent position was stronger than a pure method-of-use portfolio because US 7,498,343 claimed the active chemical entity itself. Its post-expiry position is therefore more exposed to generic substitution than products protected mainly by narrow dosing or indication patents.

Key Takeaways

  • US Patent 7,498,343 covers bedaquiline and a broad genus of quinoline-derived anti-mycobacterial compounds.
  • Claims 1 through 16 cover compounds, salts, stereoisomers, N-oxides and selected biological or stereochemical embodiments.
  • Claims 17 and 23 cover pharmaceutical compositions.
  • Claims 18 and 24 cover treatment of mycobacterial disease, including tuberculosis.
  • Claim 19 covers a defined synthetic process.
  • The patent issued on March 3, 2009, and its listed US expiration date was December 18, 2023.
  • Sirturo's five-year NCE exclusivity ended in 2017; orphan exclusivity generally ended in 2019.
  • Pediatric exclusivity extended applicable regulatory protection by approximately six months, not the underlying patent term.
  • Bedaquiline is a small molecule, so biosimilar analysis is inapplicable.
  • Generic risk after expiration depends primarily on other patents, FDA requirements, manufacturing barriers and market economics.
  • The supplied record does not establish a specific US Paragraph IV judgment or settlement involving this patent.

FAQs About US Patent 7,498,343 and Bedaquiline

Is US Patent 7,498,343 still enforceable?

Its listed US patent term expired on December 18, 2023. Any six-month pediatric extension affected the regulatory exclusivity period, not the original 20-year patent term.

Does the patent cover bedaquiline fumarate?

The compound claims cover bedaquiline and pharmaceutically acceptable acid-addition salts. Bedaquiline fumarate is an acid-addition salt and falls within the claimed salt coverage if the claimed parent compound and stereochemical form are present.

Can a generic manufacturer use a different bedaquiline synthesis route?

A different route may avoid claim 19, but it would not necessarily avoid the compound or composition claims. Those claims focus on the resulting molecule and pharmaceutical composition.

Is a bedaquiline generic a biosimilar?

No. Bedaquiline is a chemically synthesized small molecule. A US generic would generally use an ANDA or, in some circumstances, a 505(b)(2) application rather than the biosimilar pathway.

Does an expired compound patent eliminate all Sirturo market protection?

No. Expiration of US 7,498,343 removes that patent barrier, but other patents, regulatory exclusivity, formulation rights, manufacturing patents, procurement conditions and FDA requirements may still affect entry.

References

  1. United States Patent and Trademark Office. (2009). US Patent No. 7,498,343, Quinoline derivatives having antimycobacterial activity.
  2. U.S. Food and Drug Administration. (2012). FDA approves new drug for treatment-resistant forms of tuberculosis.
  3. U.S. Food and Drug Administration. (2024). Sirturo prescribing information. Johnson & Johnson.
  4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book, Sirturo patent listing.
  5. U.S. Code. 35 U.S.C. § 156; 21 U.S.C. § 355a.
  6. U.S. Food and Drug Administration. (2019). Orphan drug designation and exclusivity database: Sirturo.
  7. Stop TB Partnership. (2023). Global Drug Facility product and access information for bedaquiline.

More… ↓

⤷  Start Trial


Drugs Protected by US Patent 7,498,343

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Janssen Therap SIRTURO bedaquiline fumarate TABLET;ORAL 204384-002 May 27, 2020 RX Yes No ⤷  Start Trial ⤷  Start Trial Y Y TREATMENT OF PULMONARY MULTI-DRUG RESISTANT TUBERCULOSIS ⤷  Start Trial
Janssen Therap SIRTURO bedaquiline fumarate TABLET;ORAL 204384-001 Dec 28, 2012 RX Yes Yes ⤷  Start Trial ⤷  Start Trial Y Y TREATMENT OF PULMONARY MULTI-DRUG RESISTANT TUBERCULOSIS ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 7,498,343

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
European Patent Office 1527050 ⤷  Start Trial C300684 Netherlands ⤷  Start Trial
European Patent Office 1527050 ⤷  Start Trial PA2014032 Lithuania ⤷  Start Trial
European Patent Office 1527050 ⤷  Start Trial CA 2014 00044 Denmark ⤷  Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.